Medindia LOGIN REGISTER
Medindia
Advertisement

AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016

Friday, March 21, 2008 General News
Advertisement
WALTHAM, Mass., March 20 Decision Resources, one of theworld's leading research and advisory firms for pharmaceutical and healthcareissues, finds that the emerging drug Zactima from AstraZeneca will earn 4.7percent patient share in the treatment of non-small-cell lung cancer (NSCLC)by 2016. Surveyed oncologists indicate that they would prescribe Zactima to30 percent of their patients with advanced non-small-cell lung cancer. Also,38 percent of the physicians surveyed indicate they will use Zactima as anadjunct to current therapy rather than as a replacement. Zactima is forecastedto launch in 2008 in the United States and Europe and in 2010 in Japan.
Advertisement

According to the new report entitled Non-Small-Cell Lung Cancer(Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious;physicians indicate that the most promising emerging therapies for thetreatment of non-small-cell lung cancer will not match the current gold-standard regimen comprising Roche/Genentech/Chugai's Avastin, Bristol-MyersSquibb's Taxol, and Bristol-Myers Squibb's Paraplatin.
Advertisement

"Although some therapies in development for advanced NSCLC hold promise,most have efficacy, safety and tolerability, and/or delivery features thatmerit inferior scores compared with the Avastin/Taxol/Paraplatin regimen,"said Andrew Merron, Ph.D., analyst at Decision Resources. "A therapy's effecton overall survival is the attribute that most influences prescribingdecisions in advanced non-small-cell lung cancer. Data and the opinions ofinterviewed thought leaders indicate that Avastin/Taxol/Paraplatin hasadvantages over the sales-leading combination of Sanofi-Aventis's Taxotere andBristol-Myers Squibb's Platinol-AQ on overall survival."

About the Report

Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard TherapyContinues to Be Most Efficacious is a DecisionBase 2008 report from DecisionResources. DecisionBase 2008 combines market forecasts with clinical andcommercial end points to assess market share projections in 35 indications.These outputs are driven by quantitative and qualitative primary research.DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market shareprojections are based on prescriber surveys that compare physicians'expectations of a potential target product profile with an emerging productprofile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members ofthe media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a worldleader in market research publications, advisory services, and consultingdesigned to help clients shape strategy, allocate resources, and master theirchosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]

SOURCE Decision Resources, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close